Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.90 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441152 | 0.95 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL3517106 | 0.95 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL7899629 | 0.93 | SLC6A3 (0.96) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL6494941 | 0.81 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3516310 | 0.80 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL6500186 | 0.79 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7896269 | 0.79 | SLC6A3 (0.71) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL12585893 | 0.79 | SLC6A3 (0.71) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL10453441 | 0.78 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6494934 | 0.78 | SLC6A4 (0.63) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170059-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2170059-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
| EP-2170059-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156717-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156717-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | SLC6A3 4644/4885SLC6A4 3857/4885SLC6A2 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.